MorphoSys (ETR:MOR) received a €108.00 ($125.58) target price from investment analysts at Berenberg Bank in a research report issued to clients and investors on Thursday. The brokerage currently has a “neutral” rating on the stock. Berenberg Bank’s target price indicates a potential upside of 14.04% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the stock. Royal Bank of Canada set a €65.00 ($75.58) price objective on shares of MorphoSys and gave the company a “sell” rating in a research note on Monday, February 4th. Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the company a “neutral” rating in a research note on Tuesday, January 29th. Deutsche Bank set a €125.00 ($145.35) price objective on shares of MorphoSys and gave the company a “buy” rating in a research note on Tuesday, January 29th. Finally, JPMorgan Chase & Co. set a €135.00 ($156.98) price objective on shares of MorphoSys and gave the company a “buy” rating in a research note on Monday, January 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of €102.10 ($118.72).
Shares of MorphoSys stock opened at €94.70 ($110.12) on Thursday. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
See Also: Ex-Dividend
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.